Haploidentical Transplant for Aplastic Anemia: 96% Survival

Johns Hopkins researchers report that bone marrow transplantation from half-matched (haploidentical) family donors led to 96% survival in a small group of children, adolescents, and young adults with severe aplastic anemia. The regimen combined reduced-intensity conditioning with post-transplant cyclophosphamide. The results were published Aug. 3 in Blood Advances. They are encouraging, but the cohort is small, so read the numbers with care.

What happened

A team from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins Children's Center reviewed outcomes for 31 patients with severe aplastic anemia, aged 2 to 20 years. All were transplanted at Johns Hopkins between 2014 and 2024.

• 23 patients received a reduced-intensity transplant approach with post-transplant cyclophosphamide (PTCy). Of these, 21 got marrow from half-matched family donors and two from fully matched siblings.
• 8 patients received standard-of-care transplants from matched siblings, using a different drug combination before and after transplant.

In the PTCy group, 22 of 23 patients survived, which is the 96% figure. All 14 patients whose disease had returned or had not responded to earlier treatment survived. Eight of nine patients who had not received prior treatment survived. All eight patients in the standard matched-sibling group also survived.

Other reported findings:

• At one year, surviving patients had at least 95% donor-derived blood cells, indicating durable engraftment.
• All survivors were transfusion-independent at last follow-up.
• Serious graft-versus-host disease (GVHD) was uncommon.
• 95% of survivors no longer needed immunosuppressive drugs one year after transplant.
• Long-term complications were generally infrequent. Some patients had kidney problems or changes in reproductive hormone function.

Why it matters

Severe aplastic anemia is rare and life-threatening. The marrow fails to make enough red cells, white cells, and platelets. Transplantation can cure the disease by replacing the damaged blood-forming cells. The bottleneck is the donor. According to the researchers, only about 25% to 30% of patients have a fully matched sibling donor. Finding an unrelated matched donor is especially hard for patients from racial and ethnic minority groups who are underrepresented in donor registries.

Nearly every child shares one HLA haplotype with each parent, so a haploidentical donor is usually available quickly. The Hopkins group builds on decades of work using cyclophosphamide after transplant to control GVHD. The authors' message is that a half-matched relative may be a reasonable first option for young patients, including those who have not been treated before and those whose disease relapsed or responded incompletely to initial therapy. This is the authors' interpretation of a small dataset, not a practice-changing trial.

What to know for the USMLE: aplastic anemia, HLA matching, and GVHD

• Definition: Aplastic anemia is pancytopenia with a hypocellular (fatty) bone marrow. The marrow shows no fibrosis and no malignant infiltrate. Reticulocyte count is low.
• Pathogenesis: Most acquired cases are thought to involve T-cell-mediated autoimmune destruction of hematopoietic stem cells, often with interferon-gamma and TNF involvement. Causes include idiopathic, drugs (chloramphenicol, carbamazepine, sulfonamides), radiation, benzene, and viruses (parvovirus B19, EBV, HIV, non-A–E hepatitis).
• Inherited causes: Think Fanconi anemia (autosomal recessive DNA repair defect, positive chromosomal breakage test, short stature, café-au-lait spots, thumb/radial anomalies) and telomere disorders such as dyskeratosis congenita. Always consider these in a young patient with marrow failure.
• Clinical picture: Fatigue and pallor from anemia, infections from neutropenia, and mucosal bleeding or petechiae from thrombocytopenia. Splenomegaly and lymphadenopathy are not expected, which helps separate it from leukemia or hypersplenism.
• Diagnosis: Bone marrow biopsy confirms the diagnosis. Severity is graded by marrow cellularity plus depth of cytopenias (for example, a very low absolute neutrophil count).
• Associations: Aplastic anemia can overlap with paroxysmal nocturnal hemoglobinuria (PNH). Know that PNH is caused by PIGA mutations, loss of CD55/CD59, and complement-mediated hemolysis.
• Treatment logic: Younger patients with a matched sibling donor are classic transplant candidates. Others receive immunosuppression (anti-thymocyte globulin plus cyclosporine, often with eltrombopag). Avoid transfusions from potential family donors before transplant, because they can sensitize the recipient.
• HLA genetics: HLA genes sit on chromosome 6 and are inherited as a haplotype from each parent. Siblings have a 25% chance of being a full match. Parents are always haploidentical to their child.
• GVHD: Donor T cells attack host tissue. Acute GVHD involves skin (rash), GI tract (diarrhea), and liver (cholestatic jaundice). Chronic GVHD resembles an autoimmune or sclerotic disorder. Irradiating blood products prevents transfusion-associated GVHD.
• Cyclophosphamide: This is an alkylating agent (cross-links DNA). Its toxicities are hemorrhagic cystitis, caused by the metabolite acrolein and prevented with mesna, and, at high doses, cardiotoxicity. The rationale for giving it after transplant is that it preferentially kills rapidly dividing alloreactive T cells. Hematopoietic stem cells are relatively spared because they express high levels of aldehyde dehydrogenase.
• Conditioning: Alkylating agents and radiation are known to be gonadotoxic and can affect endocrine function. That is why late endocrine effects matter after transplant, even with reduced-intensity regimens.

Limitations

• Small sample. There were 31 patients overall and only 23 in the PTCy group. One death changes the survival rate by about four percentage points.
• Not purely haploidentical. The 96% figure covers 23 patients, of whom 21 had half-matched donors and two had matched siblings. It is not a survival rate for half-matched donors alone.
• Single center, no randomization. The study reviewed outcomes at one institution over a decade. The source gives no further design details, such as how patients were assigned to regimens. The PTCy group and the eight-patient standard group are too small for a meaningful comparison.
• Center-developed approach. The team that built the method reports the results, and outcomes at other centers may differ.
• Follow-up. The researchers say longer follow-up is needed to assess late effects. Kidney problems and reproductive hormone changes were seen in some patients, and the follow-up period is not specified in the source.
• Age range. Patients were 2 to 20 years old. The findings should not be extrapolated to older adults.

This article is educational and is not medical advice. Treatment decisions belong to patients and their transplant teams.

FAQ

What is a haploidentical bone marrow transplant?

It is a transplant from a donor who shares half of the recipient's HLA genes, typically a parent, a child, or a sibling. It widens the donor pool when no fully matched donor is available.

Why is cyclophosphamide given after the transplant?

It helps prevent GVHD, in which donor immune cells attack the patient's tissues. Conceptually, it eliminates proliferating alloreactive T cells while sparing hematopoietic stem cells, which have high aldehyde dehydrogenase activity.

Does this study prove half-matched transplants are as good as matched ones?

No. The study was small and reviewed outcomes from a single center. The authors point to earlier Hopkins work on half-matched transplants, but this report alone cannot settle the question. Larger studies and longer follow-up are needed.

Key takeaways

• In a Johns Hopkins review of 23 patients aged 2–20 with severe aplastic anemia, reduced-intensity transplant with post-transplant cyclophosphamide gave 96% survival. Twenty-one of the 23 had half-matched family donors.
• Survivors showed durable engraftment and transfusion independence, and serious GVHD was uncommon. The cohort was small, from one center, and longer follow-up is needed.
• For the USMLE, know aplastic anemia as pancytopenia with a hypocellular marrow and T-cell-mediated stem cell destruction. Also know HLA inheritance, the organ pattern of GVHD, and cyclophosphamide pharmacology.